Skip to content
Open access

Decisions in Diuretic Resistance: Oral or Subcutaneous Furosemide in Advanced Ambulatory Heart Failure?

Sep 2026 · Biomedicines · Vol 14 · 0 citations · 36 references
Medicine

TL;DR

In this exploratory real-world cohort of patients with advanced HF and refractory congestion, both outpatient furosemide strategies were associated with short-term decongestion, with differences observed in symptomatic response.

Abstract

Objectives: The objective of this study was to explore differences in short-term clinical response, renal outcomes, and healthcare resource utilization between two non-equivalent outpatient furosemide strategies: high-dose oral solution and subcutaneous administration. Methods: This retrospective observational study included 108 consecutive outpatients with advanced heart failure (HF) and diuretic resistance treated between January 2018 and December 2024. Patients received furosemide for 5 days as oral solution (250 mg/day; n = 81) or subcutaneous infusion via elastomeric pump (100 mg/day; n = 27). Primary endpoints were changes in functional status (NYHA [New York Heart Association] class), body weight, and renal function, assessed by changes in serum creatinine and estimated glomerular filtration rate and by clinically relevant worsening renal function criteria. Secondary endpoints included NT-proBNP changes and unplanned healthcare utilization at 30 days. Results: Both strategies were associated with short-term decongestion. Weight decreased similarly in both groups, with no difference in the proportion of patients achieving weight loss (oral 90% vs. subcutaneous 89%; p = 0.854). Functional improvement was more frequently observed in the oral-solution group (99% vs. 89%; p = 0.019). Renal outcomes were comparable between strategies, with no significant changes in eGFR and a similar proportion of patients experiencing a serum creatinine increase ≥0.3 mg/dL (25.9% vs. 22.2%; p = 0.85). No significant differences were observed in NT-proBNP changes. HF-related healthcare encounters decreased during the 30 days following treatment compared with the preceding 30-day period in the oral-solution group, whereas no significant within-group change was observed in the subcutaneous group. Conclusions: In this exploratory real-world cohort of patients with advanced HF and refractory congestion, both outpatient strategies were associated with short-term decongestion, with differences observed in symptomatic response. These findings are hypothesis-generating and warrant confirmation in prospective studies using comparable dosing strategies.

Read PDF

Similar papers

Review Open access Oct 2026

Early Discharge Strategy Including Subcutaneous Furosemide in Hospitalized Heart Failure.

BACKGROUND Patients hospitalized for heart failure often require prolonged intravenous diuretic therapy, contributing to costs and risks associated with inpatient care. OBJECTIVES We evaluated whether an early discharge strategy using subcutaneous furosemide delivered via a wearable minipump could increase days alive...

Ross T. Campbell, J. Osmanska, K. Docherty et al. · 1 citation
Aug 2026

Different diuretic regimes and long-term outcomes in heart failure with mildly reduced ejection fraction

Thiazide-only therapy was associated with the lowest mortality, while loop and combined diuretic therapy were linked to increased mortality and HF-rehospitalization, and Randomized trials investigating long-term diuretic therapy in HFmrEF patients are needed.

A. Schmitt, M. Behnes, M. Reinhardt et al. · 0 citations
Open access 2026

Outcomes of Continuous Infusion Versus Intermittent Bolus Injection of Furosemide in Patients with Acute Decompensated Heart Failure (ADHF): A Prospective Observational Comparative Study

Both dosing methods were effective in relieving symptoms of acute decompensated heart failure: Continuous infusion produced greater diuresis, while bolus dosing also remained effective.

Balakrishna Vuyyala, Shaik Harun Rasheed, N. Raghunandan et al. · 0 citations
Review Open access Oct 2026

EARLY INTRAVENOUS DIURETIC ADMINISTRATION AND MORTALITY IN ACUTE HEART FAILURE: A SYSTEMATIC REVIEW AND DOSE-RESPONSE META-ANALYSIS

The observed dose-response relationship supports consideration of D2D time as a potential systems-level quality metric, warranting prospective validation, and suggests amplification of the survival gradient in registries with higher baseline mortality rates.

M. Ghozali, N. D. Putri · 0 citations
Sep 2026

Urinary sodium, baseline loop diuretic dose, and short-term outcomes in ambulatory worsening heart failure: The NaU/F Index.

BACKGROUND Worsening heart failure (WHF) carries high short-term morbidity and mortality. Spot urinary sodium (NaU) is increasingly used to assess diuretic response but does not account for chronic loop diuretic exposure. OBJECTIVES To determine whether a urinary sodium-to-furosemide index (NaU/F) improves short-term...

L. Burgos, M. A. De Bortoli, R. Barovila et al. · 0 citations
Open access Sep 2026

Empagliflozin Promotes Natriuresis in Diabetic Patients with Cirrhotic Refractory Ascites: A Proof-of-Concept Study.

In this open-label, proof-of-concept study, empagliflozin was associated with improved short-term natriuretic indices over 10 days in diabetic patients with decompensated cirrhosis and refractory ascites, without serious adverse events.

Rong Shi, Yuan Gao, Yun-Yi Gao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.